Language: Spanish
References: 18
Page: 1-6
PDF size: 81.40 Kb.

ABSTRACT

Objective: To evaluate the degree of control of metabolic goals in a group of very selected type 1 and 2 diabetic patients. Methods: A cross-sectional and descriptive study was done. Patients were enrolled consecutively in the Diabetes Clinic in a tertiarycare hospital in México City during the period between april and july 2005. The population at this clinic is very selected as demonstrated by the fact that all type 2 diabetic patients were treated with drugs for diabetic control, including insulin in 43% of them. We used the goals recommended by the American Diabetes Association (ADA) as parameters to analyze and additionally included non-HDL cholesterol and the atherogenic index. Results: A total of 530 patients were included; 468 (58.8% female) had type 2 diabetes, with an average age of 58.5 years; 62 (65% female) patients had type 1 diabetes, with an average age of 31.2 years. The mean HbA1c values were 10.2 ±2.8 and 9.0 ±2.4 in type 1 and type 2 diabetic patients, respectively. The proportion of diabetic type 1 and 2 patients reaching treatment goals were 12.9% y 23.7% for HbA1c (p=0.02), 82.2% and 57.2% for both systolic and diastolic blood pressure (p=0.0001), 75.8% and 49.3% for triglycerides (p=0.0001), 45.1% and 35.6% for LDL-c (p=0.16), 51.6% and 53.4% for HDL-c (p=0.79), 56.4% and 43.3% for non- HDL cholesterol (p=0.03) and 58.0% and 55.1% for atherogenic index (p=0.66), respectively. The proportion of patients reaching all the optimal treatment goals (non-HDL cholesterol, HbA1c, arterial blood pressure and triglycerides) was 6.4% for type 1 diabetic patients and 4.4% for type 2 patients (p=0.6). Factors associated with achieving goal values in a multiple regression analysis were drug treatment for high blood pressure, use of lipid lowering drugs, insulin use and a history of stroke. Conclusions: Our results are not comparable with other publications of series evaluating the same parameters in open populations. The results show that the degree of control of eval uated risk factors is not good, principally in the case of glucemic control; it is necessary to plan strategies that help to reach these goals in diabetic patients.

REFERENCES

1. Dirección General de Información y Evaluación del Desempeño, Secretaría de Salud. Estadísticas de mortalidad en México: Muertes registradas en el año 2001. Salud Publica Mex 2003;44:565-576.

2. Stratton IM, Adler AI, Neil HA, et al. Association of glycemia and macrovascular and microvascular complications in type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000;321:405-412.

3. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-713.

4. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-393.

5. CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control and serum cholesterol level reduction for type 2 diabetes. JAMA 2002;287:2542-2551.

6. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.

7. American Diabetes Association. Standards of medical care 2005. Diabetes Care 2005;28(suppl 1):S10.

8. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003;348:2294-2303.

9. Harris MI, Eastman RC, Cowie CC, et al. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care 1999;22: 403-408.

10. Geiss LS, Rolka DB, Engelgau MM. Elevated blood pressure among US adults with diabetes, 1988-19994. Am J Prev Med 2002;22:42-48.

11. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291:335- 342.

12. Kemp TM, Barr ELM, Zimmet PZ, et al. Glucose, lipid and blood pressure control in australian adults with type 2 diabetes. Diabetes Care 2005;28:1490-1492.

13. Lepore G, Bruttomesso D, Nosari I, et al. Glycaemic control and microvascular complications in a large cohort of Italian type 1 diabetic out-patients. Diabetes Nutr Metab 2002;15:232-239.

14. Bruno G, Cavallo-Perin P, Bargero G, et al. Glycaemic control and cardiovascular risk factors in type 2 diabetes: A population-based study. Diabetes Med 1998;15:304-307.

15. Peña-Valdovinos A, Jiménez-Cruz A, Leyva-Pacheco R, Bacardi-Gascón M. Metabolism control in diabetic patients at the primary care level in México. Diabetes Res Clin Pract 1997;37:179-184.

16. Executive summary of the Third Report of the National Cholesterol Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.

17. Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease:Predicting risks by levels and ratios. Ann Intern Med 1994;121:641-617.

18. Ridker PM, Rafai N, Cook NR, et al. Non-HDL cholesterol, apolipoproteins AI and apo B100, standard lipid measures, lipids ratios and CRP as risk factors for cardiovascular disease in women. JAMA 2005;294:326-333.